How much funding has Immune Age raised?

Immune Age has raised $2.0M in total funding, most recently a Seed round.

Who are Immune Age's investors?

Immune Age's investors include Invariantes Fund.

When was Immune Age founded?

Immune Age was founded in 2024.

What industry is Immune Age in?

Immune Age operates in Biotech, Healthcare.

Immune Age

Founded 2024 · $2.0M raised

Biotech

Healthcare

Employees: 1–10
Founded: 2024
Business Model: B2B
Website: immuneage.bio

Total Funding: $2.0M
Last Round: $2.0M SeedJul 2024
Rounds: 1

About

ImmuneAGE Bio is a biotechnology startup that launched in July 2024 with $2 million in initial funding, focused on rejuvenating the immune system by targeting hematopoietic stem cells (HSCs) in the bone marrow. The company has built the first drug discovery platform designed to rejuvenate the entire immune system at its source, with a lead compound IA101. Founded on the principle that the immune system governs aging at a systemic level, ImmuneAGE Bio aims to develop therapies that may combat many age-related diseases.

Summary

Immune Age is a Biotech company, founded in 2024. It has raised $2.0M in total across 1 round, most recently a $2.0M Seed round in Jul 2024. Investors include Invariantes Fund.